Heparan Sulfate Mimetics Differentially Affect Homologous Chemokines and Attenuate Cancer Development

J Med Chem. 2021 Mar 25;64(6):3367-3380. doi: 10.1021/acs.jmedchem.0c01800. Epub 2021 Mar 8.

Abstract

Achieving selective inhibition of chemokine activity by structurally well-defined heparan sulfate (HS) or HS mimetic molecules can provide important insights into their roles in individual physiological and pathological cellular processes. Here, we report a novel tailor-made HS mimetic, which furnishes an exclusive iduronic acid (IdoA) scaffold with different sulfation patterns and oligosaccharide chain lengths as potential ligands to target chemokines. Notably, highly sulfated-IdoA tetrasaccharide (I-45) exhibited strong binding to CCL2 chemokine thereby blocking CCL2/CCR2-mediated in vitro cancer cell invasion and metastasis. Taken together, IdoA-based HS mimetics offer an alternative HS substrate to generate selective and efficient inhibitors for chemokines and pave the way to a wide range of new therapeutic applications in cancer biology and immunology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Chemokine CCL2 / metabolism
  • Heparitin Sulfate / chemistry*
  • Heparitin Sulfate / pharmacology*
  • Humans
  • Iduronic Acid / chemistry*
  • Iduronic Acid / pharmacology*
  • Models, Molecular
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Receptors, CCR2 / metabolism

Substances

  • Antineoplastic Agents
  • Chemokine CCL2
  • Receptors, CCR2
  • Iduronic Acid
  • Heparitin Sulfate